GlassScriptPhysician profile
Denise R Gooch
NPI 1023115326
$5,694.57
in general payments reported to CMS, 2019-2025
53 companies · $2,962 in 2025
The $2,962 reported for 2025 was more than what 92% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $432 · 2024: $2,301 · 2025: $2,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,585 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,584.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $495.03 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $489.02 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Novartis Pharmaceuticals Corporation | $420.84 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $314.42 | 2024-2025 | Imfinzi, Calquence, Wainua |
| Bayer Healthcare Pharmaceuticals INC. | $308.27 | 2024-2025 | |
| Glaxosmithkline, LLC. | $255.03 | 2024-2025 | Zejula, Jemperli, Nucala |
| Daiichi Sankyo INC. | $231.08 | 2024-2025 | Enhertu, Vanflyta |
| Eisai INC. | $200.34 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $199.93 | 2023 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $194.16 | 2023-2025 | Libtayo |
| Sumitomo Pharma America, INC. | $170.39 | 2024-2025 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $157.57 | 2023-2025 | Fotivda |
| Pfizer INC. | $154.69 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.71 | 2023-2025 | Fruzaqla, Alunbrig, Vpriv |
| Pharmaessentia USA Corporation | $129.68 | 2024-2025 | Besremi |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $126.47 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Abbvie INC. | $115.66 | 2024-2025 | |
| Tersera Therapeutics LLC | $105.72 | 2024-2025 | Zoladex, Xermelo, Quzyttir |
| Adc Therapeutics America, INC. | $95.57 | 2023-2025 | |
| Lilly USA, LLC | $90.37 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $79.25 | 2025 | Cabometyx |
| Genmab U.S., INC. | $67.70 | 2024-2025 | Epkinly |
| Beigene USA, INC. | $66.55 | 2024 | Brukinsa |
| Puma Biotechnology, INC. | $66.32 | 2024-2025 | |
| Sobi, INC | $61.94 | 2025 | |
| Servier Pharmaceuticals LLC | $60.98 | 2024-2025 | |
| Emd Serono, INC. | $60.53 | 2024-2025 | |
| Genentech USA, INC. | $60.26 | 2024-2025 | Venclexta, Ocrevus Zunovo, Itovebi |
| Genzyme Corporation | $58.52 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $52.19 | 2024-2025 | Monoferric |
| Beone Medicines USA, INC. | $51.47 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $50.86 | 2024-2025 | |
| Astellas Pharma US INC | $49.47 | 2024-2025 | Padcev, Vyloy |
| Ipsen Biopharmaceuticals, INC | $47.19 | 2024-2025 | Onivyde |
| Janssen Pharmaceuticals, INC | $42.78 | 2024-2025 | Erleada, Xarelto |
| Array Biopharma INC | $42.47 | 2024-2025 | Mektovi, Lorbrena, Braftovi |
| Alexion Pharmaceuticals, INC. | $33.20 | 2024 | Ultomiris |
| Blueprint Medicines Corporation | $31.19 | 2025 | Ayvakit |
| Iovance Biotherapeutics, INC. | $27.17 | 2025 | Amtagvi |
| Bioprotect Medical, INC. | $26.59 | 2025 | Bioprotect Balloon Implant System |
| Karyopharm Therapeutics INC. | $26.34 | 2024 | Xpovio |
| Stemline Therapeutics INC. | $26.04 | 2025 | Orserdu |
| Fresenius Kabi USA, LLC | $24.43 | 2025 | Stimufend |
| Spectrum Pharmaceuticals INC. | $23.06 | 2023 | Rolvedon |
| Syndax Pharmaceuticals, INC. | $22.84 | 2025 | |
| Shield Therapeutics INC | $20.16 | 2024 | |
| Legend Biotech USA INC. | $19.57 | 2025 | Carvykti |
| Kyowa Kirin, INC. | $18.65 | 2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.18 | 2025 | |
| Adaptive Biotechnologies Corporation | $17.11 | 2025 | Clonoseq |
| Azurity Pharmaceuticals, INC. | $15.84 | 2025 | Danziten |
| Amgen INC. | $15.60 | 2024 | Evenity, Prolia |
| Alnylam Pharmaceuticals INC. | $13.17 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Gooch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.